Previous 10 | Next 10 |
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today an...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 million Second...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30-day option to purchase additional shares of i...
VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four Weeks VEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) Dosing Harro...
2023-06-12 12:20:46 ET Summary Harrow Healthcare is well-positioned to grow in the US Ophthalmology market, with a branded pharma sales strategy that could boost growth and margins. The company's medium-term earnings outlook is strong, with a 2-year earnings CAGR of 159%, potentia...
2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved -3.23% on the day to $19.46. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical c...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will participate in the upcoming B. Riley Securities 23 rd Annual Institutional Investor Conference on Wednesday, May 24, 2023, at the Beverly Hilton Hotel in Beverly Hills, California. Harrow...
2023-05-12 14:12:46 ET Eyecare pharmaceutical company Harrow Health ( NASDAQ: HROW ) shed ~23% on Friday on above-average volume marking one of the sharpest intraday losses ever, even after its Q1 2023 revenue exceeded expectations. Harrow ( HROW ), a favorite on Wal...
2023-05-12 13:48:39 ET Shares of Harrow Health (NASDAQ: HROW) were down more than 24% as of 1:45 p.m. ET Friday after the company reported first-quarter earnings following the close of trading Thursday. The pharmaceutical company focuses on eye therapies. The company's stock is ...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...